miRNA Biomarkers for Thyroid Nodule Malignancy Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing thyroid cancer lack specificity in distinguishing between benign and malignant thyroid nodules, and existing markers have low sensitivity, particularly for differentiating among various types of thyroid cancers.
Innovation Solution
The use of specific microRNAs (miRNAs) such as miR-1274a, miR-1274b, miR-720, miR-1260, and others to measure expression levels in thyroid samples to identify pre-malignant or malignant nodules, allowing for improved diagnosis and prognosis of thyroid cancer types.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cytology of fine needle aspiration biopsies is used to evaluate malignancy of thyroid nodules, then the current standard method is applied, but it lacks specificity and is incapable of determining malignancy in up to 40% of cases
Solution Approach 1:
The patent changes the diagnostic parameter from cytological morphology assessment to molecular biomarker detection (miRNA expression levels). By measuring specific miRNA ratios (e.g., miR-145/miR-200b, miR-146b/miR-200b) in fine needle aspiration samples, the method transforms an subjective morphological evaluation into an objective molecular measurement, achieving 90% sensitivity and 92% specificity for distinguishing malignant from benign thyroid nodules.
Solution Approach 2:
The patent introduces miRNA expression profiles as an intermediary biomarker layer between the physical biopsy sample and the malignancy diagnosis. Instead of directly interpreting cytological features, the method uses miRNA levels as intermediate indicators that reflect the underlying molecular pathology, enabling more accurate classification of thyroid nodules including indeterminate cases.
2Loss of information
If molecular testing for mutations or translocations in genes such as BRAF, RAS, RET/PTC, and PAX8/PPARγ is applied, then additional diagnostic information is obtained, but some thyroid cancers do not carry mutations in these genes and some of these markers have low specificity for malignancy
Solution Approach 1:
The patent develops a universal miRNA-based diagnostic panel that functions across all types of thyroid cancers regardless of specific genetic mutations. The miRNA expression profile (particularly the ratio of miR-145 to miR-200b and miR-146b to miR-200b) serves as a multi-functional biomarker that detects malignancy in papillary, follicular, and other thyroid cancers without being limited to mutation-specific detection, achieving 90% sensitivity across diverse thyroid cancer types.
3Quantity of substance
If the great majority of thyroid nodules are benign, then most nodules can be non-malignant, but a continuing challenge for physicians is to accurately distinguish benign nodules from malignant nodules
Solution Approach 1:
The patent applies local quality by detecting specific miRNA expression patterns that are locally characteristic of malignant transformation within the thyroid nodule. The method identifies localized molecular changes (altered miR-145, miR-146b, and miR-200b expression) within the nodule tissue, enabling distinction between benign and malignant nodules based on their unique molecular fingerprints rather than general morphological features.
Data Source
AI summary
The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as thyroid nodules or thyroid cancer, and using the profile in the diagnosis of a patient for a condition, such as thyroid nodules or thyroid cancer.